<DOC>
	<DOCNO>NCT01654367</DOCNO>
	<brief_summary>Select patient primary breast cancer whose hormone receptor positive accept postoperative adjuvant aromatase inhibitor endocrine treatment.Treat zoledronic acid 4mg intravenous infusion every six month end aromatase treatment . Assess disease-free survival ; overall survival ; combination security , well situation bone loss .</brief_summary>
	<brief_title>Research Zoledronic Acid Aromatase Inhibitors Adjuvant Therapy Breast Cancer</brief_title>
	<detailed_description>The investigator select patient primary breast cancer whose hormone receptor positive accept postoperative adjuvant aromatase inhibitor endocrine treatment.Treat zoledronic acid 4mg intravenous infusion every six month end aromatase treatment . Assess disease-free survival ; overall survival ; combination security , well situation bone loss .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1 . Karnofsky≥70 2 . Provision inform consent 3 . Pathological confirmation breast cancer 4 . Hormone receptorpositive accept aromatase inhibitor adjuvant endocrine therapy 5 . Not previously receive treatment bisphosphonate 6 . Laboratory criterion : PLT≥100*109/L WBC≥4000/mm3 HGB≥10g/dl GOT , GPT , ALP≤2*ULN TBIL , DBIL , CCr≤1.5*ULN 7 . Surgery , radiotherapy chemotherapy finish 1 . Pregnant lactation woman 2 . History organ transplantation 3 . With mental disease 4 . With severe infection active gastrointestinal ulcer 5 . With severe liver disease ( cirrhosis ) , kidney disease , respiratory disease diabetes 6 . Diseasefree period malignant tumor le 5 year ( except cure basal cell skin cancer cervical carcinoma situ ) 7 . With heart disease 8 . Experimental drug allergy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>